Dr. Quevedo is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 1st St SW
Rochester, MN 55905Phone+1 507-284-2511
Education & Training
- Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 1993 - 1994
- Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 1990 - 1993
- Cleveland Clinic FoundationResidency, Internal Medicine, 1987 - 1990
- Cleveland Clinic FoundationInternship, Internal Medicine, 1987 - 1988
- Universidad Catolica de Santiago de GuayaquilClass of 1985
Certifications & Licensure
- FL State Medical License 2022 - 2026
- MN State Medical License 1990 - 2024
- IA State Medical License 2004 - 2008
- IL State Medical License 1996 - 1999
- LA State Medical License 1994 - 1996
- OH State Medical License 1994 - 1996
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Teacher of The Year Mayo Fellows Association, Mayo Clinic College of Medicine
Publications & Presentations
PubMed
- 102 citationsAndrogen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance.Manish Kohli, Yeung Ho, David W. Hillman, Jamie L. Van Etten, Christine Henzler
Clinical Cancer Research. 2017-08-15 - 66 citationsA Prospective Genome-Wide Study of Prostate Cancer Metastases Reveals Association of Wnt Pathway Activation and Increased Cell Cycle Proliferation with Primary Resista...Liguo Wang, Scott M. Dehm, David W. Hillman, Hugues Sicotte, Winston Tan
Annals of Oncology. 2018-02-01 - 475 citationsExosomal miR-1290 and miR-375 as Prognostic Markers in Castration-resistant Prostate CancerXiaoyi Huang, Tiezheng Yuan, Meihua Liang, Meijun Du, Shu Xia
European Urology. 2015-01-01
Journal Articles
- Long-term Treatment Outcomes for Locally Advanced Esophageal Cancer: A Single-Institution ExperienceSio TT, Wilson ZC, Stauder MC, Bhatia S, Martenson JA, Quevedo JF, Schomas DA, Miller RC, Am J Clin Oncol, 5/1/2013
- Malignant perivascular epithelioid cell tumor of the uterusBleeker JS, Quevedo JF, Folpe AL, Rare Tumors, 1/1/2012
- "Malignant" perivascular epithelioid cell neoplasm: risk stratification and treatment strategiesBleeker JS, Quevedo JF, Folpe AL, Sarcoma, 1/1/2012
- Join now to see all
Abstracts/Posters
- Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (aBCC): 18-month update of the pivotal ERIVANCE BCC study.Aleksandar S, Migden M, Basset-Seguin N, Garbe C, Gesierich A, Lao C, Miller C, Mortier L, Murrell D, Hamid O, Quevedo JF, Mackey H, Schadendorf D, ASCO, 1/1/2013
- Concurrent chemotherapy and intensity modulated radiation therapy (IMRT) in the treatment of anal cancer: a retrospective review from a large academic center.Call J, Haddock M, Quevedo JF, David L, Miller R, American Journal Of Clinical Oncology-cancer Clinical Trials, 4/1/2011
- Down-staging of locally advanced prostate cancer with anti-CTLA-4 monoclonal antibody prior to radical prostatectomy.Granberg C, Thompson RH, Quevedo JF, Karnes RJ, Frank I, Kwon ED, Blute ML, J Clin Oncol, 5/1/2009
- Join now to see all
Lectures
- Long-term Safety and Efficacy of Vismodegib in Patients With Advanced Basal Cell Carcinoma: Final Update (30-month) of the Pivotal ERIVANCE BCC Study.Chicago, IL - 6/1/2014
- GU CancersLima, Peru - 8/1/2012
- Colon CancerCuenca, Ecuador - 7/1/2012
- Join now to see all
Press Mentions
- Physics Institute Focused on Developing Countries Gets a New LeaderNovember 14th, 2019
- CUI, ICTP to Collaborate in MathsSeptember 16th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: